Partial synthetic derivatization of canrenone and characterization of its impact on the inhibitory effect on Na+/K+-ATPase activity in human heart muscle

Steroids

Volumn 63, Issue 9, 1998, Pages 464-469

  Weiland, Jürgen ^a   Megges, Rudolf ^a   Undeutsch, Bernd ^b   Schön, Rudolf ^a   Buchting, Horst ^a   Repke, Kurt R H ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

3 amino derivatives; 3 oxo 17 pregna 4,6 diene 21,17 carbolactone; 3 sulfonamido derivatives; Canrenone; Glycosidation; Hydrogenation; Na+ K+ ATPase inhibition; Reduction

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CANRENONE; CARDENOLIDE;

ARTICLE; CHEMICAL MODIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCOSYLATION; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN TISSUE; HYDROGENATION; REDUCTION; STRUCTURE ACTIVITY RELATION;

CANRENONE; ENZYME INHIBITORS; GLYCOSIDES; HUMANS; HYDROGENATION; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MYOCARDIUM; NA(+)-K(+)-EXCHANGING ATPASE; SULFONAMIDES;

EID: 0031823875     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(98)00049-X     Document Type: Article

References (30)

1. Megges R, Weiland J, Undeutsch B, Büchting H, Schön R (1997). Partial synthetic modifications of canrenone. In 17th Conference on Isoprenoids, Cracow, Poland, September 21-26, Abstracts of papers. Institute of Organic Chemistry, Polish Academy of Sciences, Warsaw, p. 71.
2. +-transporting ATPase as a step in the rational design of new inotropic steroids. Prog Med Chem 30:135-202.
3. Repke KRH, Schön R, Weiland J, Megges R, Nitz M, inventors. Neuartige Herzglykoside. DE Patent (DE-Offenlegungsschrift) 43 21 937. 1995.
4. Repke KRH, Megges R, Weiland J, Schön R (1995). Digitalis research in Berlin-Buch: Retrospective and perspective views. Angew Chem Int Ed Engl 34:282-294.
5. Repke KRH, Sweadner KJ, Weiland J, Megges R, Schön R (1996). In search for ideal inotropic steroids: Recent progress. Prog Drug Res 47:9-52.
6. Schröder R, Ramdohr B, Hüttemann U, Schüren KP (1972). Direkte positiv-inotrope Herzwirkung von Aldactone (Spironolacton, Canrenoat-Kalium). Dtsch Med Wochenschr 97: 1535-1538.
7. Lauler DP (1993). Introduction. Am J Cardiol 71:1A-2A.
8. The RALES Investigators (1996). Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78:902-907.
9. Repke KRH, Schönfeld W, Weiland J, Megges R, Hache A (1989). Steroidal inhibitors of Na/K-ATPase. In: Sandler M, Smith HJ (eds), The Design of Enzyme Inhibitors as Drugs. Oxford University Press, Oxford, pp. 435-502.
10. +-ATPase from human and guinea pig heart muscle through use of digitalis derivatives as analytical probes. Naunyn-Schmiedeberg Arch Pharmacol 351:282-292.
11. 13C-NMR-Spektroskopie. Thieme, Stuttgart.
12. Görög S (ed) (1989). Steroid Analysis in the Pharmaceutical Industry. Horwood, Chichester and Wiley, New York.
13. 13C NMR spectros-copy of sterols. In: Bohl M, Duax WL (eds), Molecular Structure and Biological Activity of Steroids. CRC Press, Boca Raton, pp. 33-90.
14. +-transporting ATPase from human cardiac muscle, human brain cortex and guinea-pig cardiac muscle. Biochem Pharmacol 35:3221-3231.
15. Tal DM (1989). 6,7-Dihydroxy-6,7-dihydrocanrenone isomers: Improved synthesis and proton NMR study. Steroids 54:113-122.
16. Cella JA, Brown EA, Burtner RR (1959). Steroidal aldosterone blockers. I. J Org Chem 24:743-748.
17. Balogh V, Fétizon M, Golfier M (1971). Oxidations with silver carbonate/Celite. V. Oxidations of phenols and related compounds. J Org Chem 36:1339-1341.
18. Ness RK, Fletcher HG Jr, Hudson CS (1951). The reaction of tribenzoyl-α-L-rhamnopyranosyl bromide with methanol. Various benzoylated derivatives of L-rhamnose. J Am Chem Soc 73:296-300.
19. Zürcher RF (1963). Protonenresonanzspektroskopie und Steroidstruktur. II. Die Lage der C-18- und C-19- Methylsignale in Abhängigkeit von den Substituenten am Steroidgerüst. Helv Chim Acta 46:2054-2088.
20. Barton DHR, Cox JD, Holness NJ (1949). The application of the method of molecular rotation differences to steroids. X. "β-Dihydroergosterol." J Chem Soc :1771-1779.
21. Fieser LF, Fieser M (1959). Steroids. Reinhold, New York, and Chapman & Hall, London.
22. Kirk, DN, Hartshorn MP (1968). Steroid Reaction Mechanisms. Elsevier, Amsterdam.
23. Johnson F, Newbold GT, Spring FS (1954). Steroids. XIII. The conversion of ergosterol into progesterone. J Chem Soc :1302-1306.
24. Daglish AF, Green J, Poole VD (1954). The synthesis of progesterone and related compounds. J Chem Soc :2627-2633.
25. Zorbach WW, Valiaveedan GD, Kashelikar DV (1962). Partial synthesis of evomonoside. J Org Chem 27:1766-1769.
26. Brown L, Boutagy J, Thomas R (1981). Cardenolide analogues. 11. Improved method for the use of Fétizon's reagent in the synthesis of cardiac glycosides. Arzneim-Forsch/Drug Res 31:1059-1064.
27. Siemann HJ, Langbein G, Richter M, Chemnitius K, Hübler D, Heinze A, inventors. Verfahren zur Herstellung von Steroidamiden. DD Patent 296 502. 1991.
28. Megges R, Weiland J, Undeutsch B, Büchting H, Schön R (1997). The nitration of canrenone with acetic anhydride/nitric acid. Steroids 62:762-766.
29. Schönfeld W, Weiland J, Lindig C, Masnyk M, Kabat MM, Kurek A, Wicha J, Repke KRH (1985). The lead structure in cardiac glycosides is 5β,14β-androstane-3β, 14-diol. Naunyn-Schmiedeberg Arch Pharmacol 329:414-426.
30. +-transporting ATPase and cardiac contractility: A contribution to the endogenous digitalis problem. J Enzyme Inhibition 2:31-36.